<html xml:lang="en-us" lang="en-us" xmlns="http://www.w3.org/1999/xhtml" xmlns:epub="http://www.idpf.org/2007/ops"><head>
    <link rel="stylesheet" type="text/css" href="../../css/base.css" />
<link rel="stylesheet" type="text/css" href="../../css/kotobeeInteractive.css" />
<link rel="stylesheet" type="text/css" href="../../css/global.css" />

    <script type="text/javascript" src="../../js/kotobeeInteractive.js"></script>
<script type="text/javascript" src="../../js/global.js"></script>

    <title>Neostigmine</title>
    

<meta name="m-checksum" content="-440422330" />
<meta charset="utf-8" />
 <meta name="kotobee-chapter" content="raw\s4izqd.xhtml" />
<meta name="kotobee-book" content="urn:uuid:a6306750-ed2a-22d8-25b7-34384db007f2" />
</head>
<body>
<p><em><strong>Neostigmine in palliative care patients should only be used under the direction of a palliative care specialist. Speak to one before starting neostigmine.</strong></em></p>

<p><strong>Indications:</strong></p>

<ul>
	<li>Acute colonic pseudo-obstruction in which supportive therapy has failed</li>
	<li>Ileus</li>
	<li>Severe constipation refractory to standard therapy</li>
</ul>

<p><strong>Contraindications:</strong></p>

<ul>
	<li>Mechanical obstruction of intestine or urinary tract</li>
	<li>Colon perforation</li>
	<li>Peritonitis&#160;</li>
	<li>Active bronchospasm</li>
	<li>Known hypersensitivity to neostigmine</li>
	<li>Cardiac disease (bradycardia, arrhythmia, recent MI within 3 months)</li>
</ul>

<p><strong>Precautions:</strong></p>

<ul>
	<li>Systolic blood pressure &lt; 90mmHg</li>
	<li>Asthma</li>
	<li>Epilepsy</li>
	<li>Parkinsonism&#160;</li>
	<li>Recent intestinal or bladder surgery</li>
</ul>

<p><strong>Before starting:</strong></p>

<ul>
	<li>Exclude a bowel obstruction (e.g. with a CT scan of the abdomen/pelvis) and other contraindications</li>
</ul>

<p><strong>Adverse effects:</strong></p>

<ul>
	<li>Documented adverse effects are more common with intravenous compared to subcutaneous administration</li>
	<li><em>Common adverse effects with subcutaneous administration:</em>
	<ul>
		<li>Bradycardia</li>
		<li>Abdominal cramping, nausea, vomiting and diarrhoea with persistent abdominal distension</li>
	</ul>
	</li>
	<li><em>Adverse effects uncommon with subcutaneous administration</em>
	<ul>
		<li>Hypotension</li>
		<li>Increased salivation</li>
		<li>Increased sweating</li>
		<li>Bronchial secretions</li>
		<li>Bronchospasm</li>
		<li>Respiratory depression</li>
		<li>Fasciculations, muscle weakness</li>
	</ul>
	</li>
</ul>

<p><strong>Commencing neostigmine:</strong></p>

<ul>
	<li>Inject 0.5mg subcutaneously twice a day</li>
</ul>

<p><strong>Monitoring requirements:</strong></p>

<ul>
	<li>Check heart rate, respiratory rate, blood pressure and pulse oximetry 4-hourly</li>
	<li>Discontinue neostigmine if bradycardia &lt; 50 beats per minute occurs</li>
	<li>Atropine can be used to reverse the muscarinic effects (bradycardia with associated hypotension)&#160;</li>
</ul>

<p><strong>Further considerations:</strong></p>

<ul>
	<li>Co-administration of glycopyrrolate (anticholinergic) may reduce risk of adverse effects including bradycardia and bronchoconstriction</li>
</ul>


</body></html>